

07-26-01

94-1647-8
PATENT
Attorney Docket No. 5008US



JUL 23 2001

CERTIFICATE OF MAILING (under 37 C.F.R. 1.10 if checked)
I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service
 as first class mail, postage prepaid (37 C.F.R. 1.8)
 "Express Mail Post Office to Addressee" service under 37 C.F.R.
Express mail label mailing number: EL740537953US

RECEIVED

Lynette Eliason
Typed name of person mailing transmittal

July 23, 2001
Date of Deposit

AUG 01 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Natalie Davis

Group Art Unit No.: 1642

Applicant(s): Noteborn et al.

Filing date: July 26, 2000

Serial No.: 09/555,981

For (title): MOLECULES INTERACTING WITH
APOPTIN

PETITION FOR EXTENSION OF TIME

Commissioner for Patents
Washington, D.C. 20231

Pursuant to 37 C.F.R. § 1.136(a), an extension of time is requested as marked below:

ACTION FOR WHICH EXTENSION IS REQUESTED

- Response to non-final office action mailed
(timely and complete response not previously filed).
- Response to final office action mailed
(application not placed in a condition for allowance by a previous timely filed response).
- Filing of Appellant's brief, notice of appeal dated .
- Filing of a continuing application having an express abandonment of this application conditioned on the granting of a filing date to the continuing application.
- Response to notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

EXTENSION REQUEST PERIOD AND FEE CALCULATION

- The period for taking the above-identified action without extension fees expired on 06/23/01.
- The period for taking the above-identified action has previously been extended (by the payment of the appropriate extension fee) to

The requested extension period (and associated fee) is:

<input checked="" type="checkbox"/> One month § 1.17(a)	<input type="checkbox"/> \$ 55.00 - small entity* <input checked="" type="checkbox"/> \$ 110.00
<input type="checkbox"/> Two months § 1.17(b)	<input type="checkbox"/> \$ 195.00 - small entity* <input type="checkbox"/> \$ 390.00
<input type="checkbox"/> Three months § 1.17(c)	<input type="checkbox"/> \$ 445.00 - small entity* <input type="checkbox"/> \$ 890.00
<input type="checkbox"/> Four months § 1.17(d)	<input type="checkbox"/> \$ 695.00 - small entity* <input type="checkbox"/> \$ 1,390.00

Comments:

- *Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.
- Any additional patent application processing fees under 37 C.F.R. § 1.17 which may be due should be charged to deposit account no. 20-1469. A duplicate copy of this petition is enclosed.

JUL 23 2001 RECORDED 00000041 05000051

110.00 00

110.00 00

Respectfully submitted,

Allen C. Turner

Reg. No. 33,041

TRASKBRITT

P.O. Box 2550

Salt Lake City, UT 84110-2550

(801) 532-1922

Date: July 23, 2001

Enclosures: Postcard, Check no. 16951 for \$110.00,
Duplicate copy of this petition



PATENT
Attorney Docket No. 5008US

CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)

I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service

as first class mail, postage prepaid (37 C.F.R. § 1.8)

"Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10

Express mail label mailing number: EL740537953US

on the date inserted below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Lynette Eliason
Typed name of person mailing transmittal

July 23, 2001

Date of Deposit

RECEIVED

AUG 01 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Examiner: Natalie Davis

Group Art Unit No.: 1642

Applicant(s): Noteborn et al.

Filing date: July 26, 2000

Serial No.: 09/555,981

For (title): MOLECULES INTERACTING WITH APOPTIN

COMMUNICATION TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

Postcard receipt acknowledgment (attached to the front of this transmittal).
 Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fees may be charged to deposit account no. 20-1469.
 Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.
 Preliminary amendment.
 Amendment or other communication in response to the non-final office action mailed.
 Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed.
 Petition for Extension of Time in duplicate with check no. 16951 in the amount of \$110.00.
 Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of).
 Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.
 Response to notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Remarks:

An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

1	2	3	\$EXTRA
Total claims	-	=	x 18.00 =
Indep. claims	-	=	x 78.00 =
First presentation of a multiple dep. claim (+260.00)			
SUBTOTAL			
Reduction for small entity - 50% of subtotal*			
TOTAL ADDITIONAL FEE (subtotal minus any reduction)			

*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

1 Claims remaining after amendment.

2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.

3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.

Respectfully submitted,

Allen C. Turner
Reg. No. 33,041
TRASKBRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550
(801) 532-1922

Date: July 23, 2001

Enclosures: As identified above

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE